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Nicotinamide adenine dinucleotide (NAD) is an essential coenzyme involved in REDOX reactions and oxidative
stress defense systems. Furthermore, NAD is used as substrate by proteins that regulate essential cellular functions
as DNA repair, genetic, and signal transduction, among many others. NAD biosynthesis can be completed through
the de novo and salvage pathways, which converge at the common step catalyzed by the nicotinate/nicotinamide
mononucleotide adenylyltransferase (NMNAT EC: 2.7.7.1/18). Here, we report the kinetic characterization of the
NMNAT of Leishmania braziliensis (LbNMNAT), one of the etiological agents of leishmaniasis, a relevant parasitic
disease. The expression and homogeneous purification of the recombinant 6xHis-LbNMNAT protein was carried
out and its kinetic study, which included analysis of Km, Vmax, Kcat and the equilibrium constant (KD) for both the
forward and reverse reactions, was completed. The oligomeric state of the recombinant 6xHis-LbNMNAT protein
was studied through size exclusion chromatography. Our results indicated the highest and lowest Km values for
ATP and NAD, respectively. According to the calculated KD, the pyrophosphorolytic cleavage of NAD is favored in
vitro. Moreover, the recombinant 6xHis-LbNMNAT protein showed a monomeric state, although it exhibits a
structural element involved in potential subunits interaction. Altogether, our results denote notable differences of
the LbNMNAT protein in relation to the human orthologs HsNMNAT1-3. These differences constitute initial
findings that have to be continued to finally propose the NMNAT as a promissory pharmacological target in
L. braziliensis.1. Introduction
Leishmania braziliensis is one of the etiological agents of leishmaniasis,
a set of relevant illnesses in tropical countries. Current control strategies
depend on chemotherapy to treat infection and insecticides to reduce
transmission [1]. Nowadays, effective vaccines for humans have not been
developed [2]. The identification of new pharmacological targets and the
implementation of rational therapeutic and long-lasting strategies,
require research efforts focused on the molecular and biochemical
characterization of the pathogen. In this sense, the study of the nicotin-
amide adenine dinucleotide (NAD) proves to be suitable given the
essential functions that it performs.
NAD and its phosphorylated form (NADP) participate as coenzymes in
energy metabolism and in oxidative stress defense systems. Additionally,
NAD is used as a substrate by enzymes involved in cellular processes such
as DNA repair and cellular death, calcium mobilization, circadian cycle
and RNA stability, among others [3, 4]. In Leishmania, NAD participatesRamírez Hernandez).
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evier Ltd. This is an open access ain energy metabolism, anti-oxidative systems, proliferation, differentia-
tion and cellular death processes through sirtuins [5, 6], whose charac-
terization has been completed in L. amazonensis (LaSIR2) [7], L. major
(LmSIR2) [8,9] and L. infantum (LiSIR2) [10].
The biosynthesis of NAD is carried out through the de novo and salvage
pathways. Even though these routes employ different chemical pre-
cursors and intermediaries, both converge in the step catalyzed by the
nicotinate/nicotinamide mononucleotide adenylyltransferase (NMNAT;
EC: 2.7.7.1/18) [11], an essential enzyme [11, 12, 13, 14]. The NMNAT
has been investigated in archaebacteria, bacteria, parasites, yeast, in-
sects, plants and mammals. In humans three isoenzymes have been
described (HsNMNAT1-3), which exhibit particular kinetic and oligo-
meric states [15].
A relevant aspect of the NMNATs refers to the preference for NAD
precursors (NMN or NAMN). Even though the majority of NMNATs can
employ both substrates, some of them possess a fixed selectivity. For
instance, Escherichia coli has two isoenzymes: NadD and NadR, the formerh 2020
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substrate, while the NadR is 170 times faster adenylating NMN [16]. On
their part, the NMNATs of archaebacteria prefer NMN as a substrate [17,
18, 19]. In Saccharomyces cerevisiae the isoenzymes ScNMNAT1-2 present
differential selectivity, while in Arabidopsis thaliana (AtNMNAT) [20]
and Homo sapiens (HsNMNAT1 and 3), NAD and NAAD are produced
with similar efficiency [14].
NAD biosynthesis is considered as a therapeutic target against cancer,
neurodegenerative diseases and pathogenic organisms [21, 22, 23, 24,
25, 26]. In this context, the characterization of the NMNAT of L. brazil-
iensis (LbNMNAT) enzyme and the identification of differences in
contrast to the human orthologs, comprise crucial points for the devel-
opment of potential new control strategies of Leishmania.
The first experimental evidence on the NADmetabolism in Leishmania
was reported by our research group through the identification, cloning
and expression of the recombinant 6xHis-LbNMNAT protein [27]. In
addition, protein-protein interaction (PPI) analysis based on the
LbNMNAT enzyme revealed proteins involved in RNA binding, redox
homeostasis, and translation [28].
In this study, the kinetic characterization for the forward and reverse
reaction, the use of the NAMN as a substrate, as well as the evaluation of
the oligomeric states of the 6xHis-LbNMNAT protein is shown. Our evi-
dences denote differences among the LbNMNAT protein and the human
orthologs HsNMNAT1-3, suggesting that the NAD biosynthesis in Leish-
mania could be manipulated as a pharmacological target.
2. Materials and methods
2.1. Expression of the recombinant 6xHis-LbNMNAT protein
The previously constructed pQE30-LbNMNAT plasmid [27] allows
the expression of the LbNMNAT protein fussed with the 6xHis tag at the
N-terminus, under the control of the T5 promoter. The recombinant
plasmid was used to transform chemically competent E. coliM15 cells by
a heat shock protocol. The resulting clones were pre-inoculated in LB
media supplemented with 100 μg/mL of ampicillin and 50 μg/mL of
kanamycin, ON at 37 C with constant agitation. The pre-inoculums were
diluted 1:50 in LBmedium and incubated at 37 Cwith constant agitation
until an OD600 nm ¼ 0.6–0.8. The induction of the recombinant
6xHis-LbNMNAT protein was carried out with IPTG (final concentration
0.5 mM) ON at 26 C with constant agitation. The induced samples were
analyzed by SDS-PAGE in discontinuous gels.
2.2. Preparation of soluble extracts of the recombinant 6xHis-LbNMNAT
protein
The induced cells were collected by centrifugation at 8000 rpm for 10
min at 4 C. The pellets were resuspended in lysis buffer (0.5 mg/mL
lisozyme, protease inhibitor cocktail (Sigma P8340) (cocktail:extract,
1:400), 500 mM NaCl, 25 mM NaH2PO4 pH 8.0/NaOH, 10 mM imid-
azole, 2 mM MgCl2, 1% V/V glycerol) adding 7 mL/g of wet cell weight.
The resuspension was incubated 1 h at 4 C with constant agitation,
sonicated on ice (50 % amplitude, cycles: 15 s pulse, 45 s rest. Total
sonication time: 3 min) and centrifuged at 14000 rpm for 30 min at 4 C.
Soluble and insoluble fractions were collected.
2.3. Purification of the recombinant 6xHis-LbNMNAT protein by IMAC
The recombinant protein was purified by immobilized metals affinity
chromatography (IMAC). The soluble fraction (20 mL) was incubated
with the Ni-NTA resin (Qiagen) (0.5 mL), previously equilibrated with
binding buffer (500 mM NaCl, 25 mM NaH2PO4 pH 8.0/NaOH, 10 mM
imidazole) for 1 h on ice with constant agitation (Qiagen). This mixture
was centrifuged at 3000 rpm for 3 min at 4 C and the supernatant (non
binding proteins) separated from the precipitate, which was washed with
10 mL of wash buffer 1 (500 mM NaCl, 25 mM NaH2PO4 pH 8.0/NaOH,2
10 mM imidazole). Then, a wash with 4 mL of wash buffer 2 was done
(500 mM NaCl, 25 mM NaH2PO4 pH 8.0/NaOH, 30 mM imidazole).
Then, the resin was resuspended with 2 mL of wash buffer 3 (500 mM
NaCl, 25 mM NaH2PO4 pH 8.0/NaOH, 75 mM imidazole) and a chro-
matography column was packed by gravity, collecting the corresponding
wash. Finally, 4 elutions with 0.5 mL of elution buffer were carried out
(500 mM NaCl, 25 mM NaH2PO4 pH 8.0/NaOH, 300 mM imidazole).
Each eluate was dialyzed against 1 L of dialysis buffer (500 mM NaCl, 25
mM NaH2PO4 pH 8.0/NaOH, 0,5 mM DTT) ON at 4 C. The dialyzed
samples were supplemented with 1 mM DTT and 10 % V/V glycerol and
stored at -80 C. The purification steps were analyzed by SDS-PAGE in
discontinuous gels.
2.4. Purification of the recombinant 6xHis-LbNMNAT protein by SEC
The homogeneous purification of the recombinant 6xHis-LbNMNAT
protein was achieved by size exclusion chromatography (SEC), inject-
ing 500 μg of IMAC's eluates in a Superdex 200 10/300 GL column (GE
Healthcare Life Sciences), previously equilibrated in equilibrium buffer
(300 mM NaCl, 50 mM NaH2PO4 pH 8.0/NaOH, 0.5 mM DTT). The
chromatography was carried out employing the €Akta Purifier system (GE
Healthcare Life Sciences) at 4 Cwith a flow of 0.5 mL/min. The collected
fractions were monitored by absorbance at 280 nm, SDS-PAGE in
discontinuous gels and coupled activity assays. Upon confirmation of the
enzymatic activity of the eluted recombinant 6xHis-LbNMNAT protein,
the chromatogram was used to calculate the molecular weight of the
protein in order to infer its oligomeric organization. Consequently, a
calibration curve was constructed using molecular weight standards,
which were subjected to the same chromatographic protocol. Lysozyme
(14 kDa), carbonic anhydrase (29 kDa), BSA (66 kDa) (GE Healthcare
Life Sciences) and the recombinant 6xHis-HsNMNAT1 protein (32 kDa,
which was purified in this study (Supplementary Figure 1)) were all
mixed and applied into the SEC column. The void volume was deter-
mined with blue dextran (Sigma). The partition coefficient (Kav) of each
standard was used to plot the corresponding calibration curve (Kav vs Log
MW). The equation of the curve was used to determine the molecular
weight of the recombinant 6xHis-LbNMNAT protein.
2.5. Coupled and direct enzymatic assays
The following protocols were standardized based on previous reports
[15, 29]. In the coupled assays, a mixture of reaction that contained 40
mM ethanol, 25 mM HEPES/KOH pH 7.4, 10 mM MgCl2, 1.25 mM ATP
(Sigma), 1.25 mM NMN (Sigma) and 10 U of alcohol dehydrogenase
(ADH) (Sigma) was used. This mixture was dispensed in plastic cuvettes
and, upon adding 2.5 μg of the recombinant 6xHis-LbNMNAT protein;
the reaction was initiated. The assays were carried out in a volume of 1
mL at 20 C, measuring absorbance at 340 nm for 5 min. In the direct
enzymatic assays, a mixture of reaction that contained 25 mM HEPE-
S/KOH pH 7.4, 10 mM MgCl2, 1.25 mM ATP and 1.25 mM NMN was
used. Additionally, direct assays were carried out with 1.25 mM ATP and
1.25 mM NAMN (Sigma) to evaluate the mononucleotide specificity of
the recombinant 6xHis-LbNMNAT protein. The reaction started upon
adding 2.5 μg of the enzyme. The enzymatic reactions were incubated at
20 C for 5 min and stopped by filtration through a Centricon device
(Millipore, MWCO 30 kDa). The filtered samples were analyzed through
RP-HPLC.
2.6. RP-HPLC analysis
The analysis was done using the Shimadzu Prominence System and
the Eclipse XDB-C18 column (150  4.6 mm, 5 μm, Agilent). Solvents A
110 mM potassium phosphate buffer, pH 5.8, 8 mM tetra bromide-n-
butyl ammonium (TBAB) and B (methanol) were employed to carry
out the following elution gradient, varying the % of solvent B: 4%, 6.5
min, 30%, 7 min, 36%, 3 min, 4%, 3.5 min. A flow of 1 mL/min was used,
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10 μL of the samples were injected and the analytes were detected at 254
nm. To carry out quantitative analysis, calibration curves of NAD, NMN
and ATP were constructed.
2.7. Determination of kinetics parameters
The kinetic parameters Michaelis-Menten (Km), maximum velocity
(Vmax) and turnover number (Kcat) of the recombinant 6xHis-LbNMNAT
protein were determined maintaining saturating concentrations of one
of the substrates while varying the concentration of the other. The exact
concentrations for each substrate are indicated in the corresponding re-
sults (Figure 3). The coupled enzymatic assay was used to determine the
parameters for the substrates NMN and ATP. The direct enzymatic assay
was used to determine the parameters for NAD (Sigma) and PPi (Sigma).
The initial reaction rate, expressed as μmol of NAD produced/min*mg
protein, was determined from the lineal region of the corresponding
progression curves. Data obtained were used to carry out non-linear
(Michaelis-Menten) and linear (Hanes-Woolf) regression plots, using
the GraphPad Prism version 6 program. The enzymatic reactions
analyzed in the direct (I) and coupled (II) assays can be described as
follows:
I: NMNþATP ⇄NMNATNADþ þ PPi
II: NADþ þETHANOL→ADHNADHþ Hþ þ ACETALDEHYDE
2.8. Determination of the equilibrium constant (KD)
Direct enzymatic assays were carried out for 2, 4 and 24 h using 500 μM
of the substrates NMN andATP or 1mMof the substrates NAD and PPi. The
respective quantity of the synthesized products was determined using
appropriate calibration curves. The KD was calculated with the formula KD
¼ [product 1] X [product 2]/[substrate 1] X [substrate 2] [15].
2.9. Protein determination
The protein concentration was determined by the Bradford method
using BSA as a standard. Specifically, the Pierce BCA Protein Assay Kit
(Thermo Scientific) was used.3
3. Results
3.1. The recombinant 6xHis-LbNMNAT protein was purified to
homogeneity and eluted as an active monomer from the SEC column
With the objective of carrying out a kinetic study of the LbNMNAT
enzyme, the purification of the recombinant 6xHis-LbNMNAT protein
(36 kDa) was undertaken in this study. Initially, an IMAC protocol was
completed using the Ni-NTA resin. The collected eluates were subjected
to SEC in a Superdex 200 10/300 GL column, which resulted in a pure
preparation of the recombinant 6xHis-LbNMNAT protein, according to
SDS-PAGE (Figure 1A).
The SEC chromatogram indicated a peak with an elution volume of
16.01 mL for the recombinant 6xHis-LbNMNAT protein (Figure 1B).
Analysis of the fractions contained in the mentioned peak, through
coupled enzymatic assays, confirmed the functionality of the 6xHis-
LbNMNAT protein (Figure 1C). In addition, the SEC experiment was
used to analyze the oligomeric organization of the recombinant 6xHis-
LbNMNAT protein, plotting a calibration curve (Kav vs Log MW), whose
R2 value indicated linearity among the variables (Figure 1D).
A MW value of 41.98 kDa was obtained for the recombinant 6xHis-
LbNMNAT protein, which is close to the theoretical MW of the mono-
meric recombinant protein (36 kDa). This result indicates that under the
experimental conditions of this study, the 6xHis-LbNMNAT protein does
not show a oligomeric assemblie, as observed for E. coli (EcNMNAT) [30],
Pseudomonas aeruginosa (PaNMNAT) [31] and the human iso-enzyme
HsNMNAT2 [32]. On the other hand, HsNMNAT1 and HsNMNAT3
display hexamers and tetramers, respectively [14].
NMNATs that exhibit quaternary structure contain a structural
element involved in the interaction among subunits. This structural
element, consisting of a loop or a loop attached to a β sheet, connects
the Rossmann fold with the C-terminal domain of these NMNATs. In
order to verify the existence of this structural element in the LbNMNAT
protein, a predictive model of the tertiary structure of this enzyme was
constructed; applying a described methodology [27]. The inspection of
the model revealed the presence of the mentioned structural element
(Figure 2). This bioinformatics evidence suggests that the LbNMNAT
protein could establish oligomeric assemblies, although in our SEC
protocol, the recombinant 6xHis-LbNMNAT protein eluted as an active
monomer.Figure 1. Purification of the recombinant 6xHis-
LbNMNAT protein by IMAC-SEC. A. SDS-PAGE12%.
Lanes: 1. Soluble starting fraction of E. coli M15; 2.
Eluate from IMAC injected into the SEC column; 3.
Fraction 50 obtained in the SEC protocol. Proteins
were visualized with Coomassie R-250. M, molecular
weight marker (kDa). B. The recombinant 6xHis-
LbNMNAT protein eluated from the SEC column at
an elution volume of 16.01 mL. The observed peak
comprised fractions 49–51. C. The enzymatic activity
of the recombinant 6xHis-LbNMNAT protein con-
tained in fractions 49–51 was verified by enzymatic
assays coupled to ADH. D. Calibration curve (Kav VS
Log MW) used to analyze the oligomeric organization
of the recombinant 6xHis-LbNMNAT protein. The or-
ange circles represent protein standards lysozyme (14
kDa), carbonic anhydrase (29 kDa), BSA (66 kDa) and
6xHis-HsNMNAT1 (32 kDa, Supplementary Figure 1),
which exhibits a hexameric organization in SEC (192
kDa).
Figure 2. The predictive model of the LbNMNAT protein displays the
structural element required to establish oligomers. The predictive model
exhibits a structural element (orange) connecting the Rossmann fold (gray) with
the C-terminal (blue). This element is common to the NMNATs showing qua-
ternary structure [35]. Image generated with the UCSF Chimera program [43].
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protein
In the enzymatic characterization of the recombinant 6xHis-
LbNMNAT protein, preliminary data about the optimal experimental
conditions of catalytic activity as buffer systems, pH, temperature andFigure 3. Kinetic parameters of the recombinant 6xHis-LbNMNAT protein. Usin
the values of Km and Vmax were determined. Saturating concentrations of the follow
mean þ standard deviation (n ¼ 3).
4
enzyme cofactors, were considered, under which the following kinetic
parameters were determined: Michaelis Menten constant (Km), maximum
velocity (Vmax) and turnover number (Kcat).
The determination of the Km values for the NMN and ATP substrates
was performed by coupled enzymatic assays to ADH, while for the NAD
and PPi substrates direct enzymatic assays were carried out. The election
of the type of assay was conducted considering that the determination of
the kinetic parameters of the human iso-enzymes 6xHis-HsNMNAT1-3
has been performed in the same way [15, 29]. The data analysis was
based on non-linear (Michaelis-Menten) and linear (Hanes-Woolf)
regression methods, which generated consistent results with each other
(Figure 3 and Table 1). The kinetic parameters of the 6xHis-LbNMNAT
protein differ slightly among this study and a previous one [27]. This
variation could be explained on the basis of different enzyme prepara-
tions; in this study, we describe a methodological advance to purify to
homogeneity the 6xHis-LbNMNAT through a coupled IMAC-SEC proto-
col without contaminants that could interfere with the kinetic charac-
terization of the enzyme.
Regarding the assessed substrates, the recombinant 6xHis-LbNMNAT
protein exhibits the lowest and highest Km values for ATP and NAD,
respectively. Concerning NMN and PPi, their Km values were determined
within the range reported for other NMNATs. When comparing the Km
values for the substrates involved in the direct reaction (NMN and ATP),
it was observed that the recombinant protein has a lower Km value for
ATP. This result is similar to those reported for E. coli (NadR) and Sul-
folobus solfataricus NMNATs, which appears to be an exception in relation
to other NMNATs characterized so far (http://www.brenda-en
zymes.org).
The maximum velocity analysis revealed that the recombinant 6xHis-
LbNMNAT protein is faster catalyzing the degradation of NAD, in
contrast to its ability to synthesize it. Specifically, values of ~20 μmol/
min*mg were obtained for the degradation of NAD in relation to ~0.2
μmol/min*mg for its synthesis (Table 1). The calculated Kcat confirmed
this result, as the enzyme consumes ~16 molecules of NAD/s in the
reverse reaction VS 0.2 molecules of NMN/s in the direct reaction. A
similar trend has been reported for iso-enzymes HsNMNAT1-3, which are
three times more efficient degrading NAD in vitro [15].
Due to the recombinant 6xHis-LbNMNAT protein can catalyze both
forward and reverse reactions; the equilibrium constant (KD) was deter-
mined for these reactions quantifying the synthesized products (Sup-
plementary Figure 2). The KD indicated that the reverse reaction is
favored in vitro (Table 2). From a biological perspective, trypanosomatidsg non-linear (Michaelis-Menten) and linear (Hanes-Woolf) regression methods,
ing substrates were used: A. ATP. B. NMN. C. PPi. D. NAD. Data presented as the
Table 1. Kinetic parameters of the 6xHis-LbNMNAT protein.
Substrate Km (μM) Vmax (μmol/min*mg) Turnover number, Kcat (sec1)
Linear Non linear Linear Non linear Linear Non linear
NMN 178,7 166,7 0,3 0,3 0,2 0,2
ATP 3,5 2,9 0,2 0,2 0,1 0,1
NAD 412,2 470,2 27,6 28,7 16,6 17,2
PPi 166,6 196 18,7 19,2 11,2 11,5
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regulate its physiological availability [33, 34]. Low concentrations of free
PPi would limit the reverse reaction of the NMNAT, which is why the
adenylyltransferase activity would prevail in vivo.
Given that most NMNATs can employ NAMN as a substrate to syn-
thesize NAAD, the ability of the recombinant 6xHis-LbNMNAT protein to
catalyze this reaction, was evaluated. Analysis of direct enzymatic assays
by RP-HPLC showed the synthesis of the product NAAD by the 6xHis-
LbNMNAT enzyme, as it happened with the positive control (6xHis-
HsNMNAT3) (Figure 4). This result agrees with previous observations in
L. infantum, pathogen in which the existence of the nicotinamidase (EC:
3.5.1.19) was demonstrated, indicating the existing of the recycling
pathway of NA (Preiss-Handler route) to synthesize NAMN. This mono-
nucleotide is a substrate of the NMNAT, which then synthesizes NAAD
[5], as showed herein.
4. Discussion
The NAD synthesis pathways converge in the step catalyzed by the
NMNAT enzyme. For this reason and focused on identifying differences
between the LbNMNAT protein and the human orthologs (HsNMNAT1-
3), the kinetic characterization of the recombinant 6xHis-LbNMNAT
protein was conducted in this study. The expression of that protein was
carried out from the pQE30 vector as it has been done for the recombi-
nant 6xHis-HsNMNAT1 and 3 proteins [15]. The homogeneous purifi-
cation of the 6xHis-LbNMNAT protein established the starting point for
future structural studies of the protein, such as X-ray crystallography, a
technique that requires pure preparations.
The oligomeric state of the recombinant 6xHis-LbNMNAT protein was
analyzed through structural and functional experiments, which revealed
that the recombinant protein eluted as an active monomer from the SEC
column (Figure 1). Similar observations have been reported for E. coli
(NAdD), P. aeruginosa and H. sapiens (HsNMNAT2) NMNATs, monomeric
enzymes capable of synthesizing NAD [30, 31]. This result confirms that
oligomerization is not a mandatory requirement for the enzymatic
functioning of all NMNATs. Similarly, the existence of the structural
element involved in the oligomerization of NMNATs [35], does not imply
that these proteins establish quaternary structure.
Nonetheless, our SEC assay was performed in the absence of sub-
strates and cofactors. Other researchers have suggested that the NMNAT
of Bacillus subtilis establishes tetramers in the absence of substrates andTable 2. Equilibrium constant (KD) of the 6xHis-LbNMNAT protein.
FORWARD REACTION (NMN þ ATP)
Time (h) NAD (μM) PPi (μM) ATP (
2 132,9 132,9 341,5
4 174,1 174,1 455,9
24 129,9 129,9 339,3
REVERSE REACTION (NAD þ PPi)
Time (h) NAD (μM) PPi (μM) ATP (
2 288,9 288,9 898,9
4 273,4 273,4 876,6
24 215,7 215,7 705,7
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dimers in the presence of its product (NAAD) [36]. Consequently, it
would be appropriate to repeat the SEC assay or to implement other
analytical techniques in the presence of substrates and/or products,
evaluating possible changes in the oligomeric organization of the re-
combinant protein. Dynamic Light Scattering (DLS) assays were initiated
using the recombinant 6xHis-LbNMNAT protein in the absence or pres-
ence of ATP and NMN. Preliminary results have indicated that the hy-
drodynamic radius of the recombinant protein varies in the presence of
ATP, suggesting that this substrate modulates the oligomerization state of
the LbNMNAT protein.
Regarding the kinetic characterization of the recombinant 6xHis-
LbNMNAT protein, an important aspect related to the Km determined
for ATP (~3 μM) (Table 1) was observed: This constant is up to 3 orders
of minor magnitude with respect to other NMNATs characterized so far,
except for NMNATs of prokaryotic organisms such as E. coli (NadR) and
S. solfataricus, which also exhibit low Km constants for ATP (Km: 1.7 and
0.08 μM, respectively) [18, 37]. Assuming a limited availability of ATP in
Leishmania, the low Km value for ATP of the LbNMNAT protein would be
reasonable, given the importance of NAD in oxidative stress defense
systems and proliferation. Additionally, other enzymes of the parasite
that also employ ATP as a substrate exhibit variable values of Km for this
molecule (hexokinase 300 μM, phosphoenolpyruvate carboxykinase 54
μM, Ecto-ATPase 980 μM and adenylate kinase 2104 μM) [38, 39, 40,
41]. From this viewpoint, low Km for ATP is not a trend among Leishmania
enzymes, but seems to be a particular case for its NMNAT, a key enzyme
for energy metabolism and cell signaling.
The Km for ATP of the recombinant 6xHis-LbNMNAT protein could be
used to design potential inhibitors based on the structure of that sub-
strate, contributing to the development of new strategies to control the
parasite. Similarly, the importance of the NMNAT protein in Plasmodium
falciparum has encouraged the development and implementation of
specific enzymatic inhibitors, capable of negatively affecting its growth in
vivo [42]. However, in the Leishmaniamodel such inhibitors have not yet
been reported.
Considering the Km of the recombinant 6xHis-LbNMNAT enzyme for
NAD and PPi, differences were observed with those constants reported
for the iso-enzymes HsNMNAT1-3. For example, the Km constants for
NAD are lower in the three human iso-enzymes (Km: 59, 70 and 130 VS
470 μM for the parasite) while the Km for PPi is lower in L. braziliensis (Km:








Figure 4. The recombinant 6xHis-LbNMNAT protein synthesizes NAAD. The synthesis of NAAD was verified by direct enzymatic assays analyzed by RP-HPLC
using the following samples: A. Reaction buffer. B. Recombinant 6xHis-HsNMNAT3 protein (positive control). C. Recombinant 6xHis-LbNMNAT protein. 2.5 μg of
each enzyme were used. The corresponding retention times for the NAMN and ATP substrates are indicated, as well as for the NAAD product. D. Multiple alignment of
the primary structure of certain NMNATs that use NMN and NAMN as substrates. A section of the alignment is indicated, highlighting the conserved asparagine residue
involved in the binding with both substrates. Alignment generated with the CLC Sequence Viewer program version 7.5 (ClustalW algorithm). Pyrococcus abyssi (Pab,
WP_010868691.1), Methanocaldococcus jannaschii (Mja, AAB98533.1), Methanothermobacter thermautotrophicus (Mth, PDB 4YP7), Methanolobus tindarius (Mti,
WP_048135196.1).
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and the human iso-enzymes, differ considerably.
The analysis of the Vmax, the Kcat and the KD of the recombinant 6xHis-
LbNMNAT protein, indicated that this enzyme is faster, more efficient
and promotes the catalysis of the reverse reaction in in vitro conditions
(Tables 1 and 2). That is, the ATP and NMN synthesis from NAD and PPi,
is the reaction that prevails under the experimental conditions reported
in this study. In the parasite's in vivo context, is possible to suggest an
explanation for this result: the PPi is limited to the acidocalcisomes,
restricting the reverse reaction catalysis by the LbNMNAT. However, the
possibility that the reverse reaction is catalyzed under energetic stress
conditions, in order to synthesize ATP, is a scientific exploration route
that has not yet been undertaken.
Depending on the organism, the NMNATs display differential selec-
tivity for the NMN or NAMN substrates to synthesize NAD or NAAD,
respectively. While archaebacteria prefer NMN, eubacteria use NAMN6
[13, 14]. Meanwhile, the human iso-enzymes HsNMNAT1-3 may syn-
thesize both NAD and NAAD [15], as was observed for the recombinant
6xHis-LbNMNAT protein (Figure 4). This result is supported by previous
studies that have reported the synthesis of NAAD in L. infantum [5]; the
parasite depends on the activity of the nicotinamidase enzyme for NAD
recycling and proliferation. This enzyme catalyzes conversion of nico-
tinamide to nicotinic acid, which can be converted to NAMN in the
Preiss-Handler pathway. Moreover, NMNATs using both NMN and
NAMN to synthesize NAD or NAAD, as those of archaebacteria, retain an
asparagine residue around position 81 [19], residue also found in the
LbNMNAT protein (Figure 4D).
5. Conclusion
A study on the metabolism of NAD in L. braziliensis was performed,
focused on the central enzyme of its biosynthesis, the LbNMNAT. The
L.E. Contreras Rodríguez et al. Heliyon 6 (2020) e03733evidence obtained indicated differences among the parasite's NMNAT
and the human orthologs HsNMNAT1-3 in terms of kinetic parameters
and oligomeric organization. These findings have to be continued to
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